What atropine concentration is optimal for myopia control in school‑age children (6–12 years) with progressive myopia and no contraindications?

Optimal Atropine Concentration for Myopia Control in Children

For school-age children (6-12 years) with progressive myopia, atropine 0.05% represents the optimal concentration, offering double the efficacy of 0.01% while maintaining an acceptable safety profile with minimal visual side effects. 1

Evidence-Based Concentration Selection

Primary Recommendation: 0.05% Atropine

The LAMP (Low-Concentration Atropine for Myopia Progression) study, a randomized double-masked clinical trial, demonstrated that 0.05% atropine was the optimal concentration among low-dose options (0.05%, 0.025%, 0.01%), with efficacy double that of 0.01% atropine over 2 years. 1

Key efficacy data over 2 years: 2

• 0.05% atropine: Mean SE progression 0.55±0.86 D; AL elongation 0.39±0.35 mm
• 0.025% atropine: Mean SE progression 0.85±0.73 D; AL elongation 0.50±0.33 mm
• 0.01% atropine: Mean SE progression 1.12±0.85 D; AL elongation 0.59±0.38 mm

The efficacy of 0.05% remained consistent in year 2 compared to year 1, with continued benefit demonstrated in year 3 compared to stopping treatment. 1

Concentration-Dependent Efficacy Pattern

A critical finding from network meta-analysis is that efficacy ranking is NOT proportional to dose - meaning 0.05% atropine achieves comparable efficacy to high-dose atropine (1% and 0.5%) while avoiding their significant side effects. 3 The ranking probability shows 1%, 0.5%, and 0.05% as the three most beneficial concentrations for myopia control. 3

Safety and Tolerability Profile

Side Effect Considerations

Lower concentrations dramatically reduce adverse effects while maintaining efficacy: 1

• 0.01% atropine: Minimal side effects, well-tolerated, but less effective
• 0.05% atropine: Minimal accommodation loss and pupil changes, well-tolerated, superior efficacy
• 0.1% and 0.5% atropine: More visual side effects including photophobia, accommodation loss requiring bifocals for near work
• 1% atropine: Strongest efficacy but limited by blurred near vision and photophobia 4

Photophobia rates are concentration-dependent but remain low at 0.05% - recent data shows 0.025% atropine had photophobia rates of 1.0%-10.9%, which were mostly mild. 5

Rebound Phenomenon

A critical advantage of lower concentrations is reduced rebound after cessation. A more significant myopic rebound occurs after 0.5% atropine treatment cessation compared with 0.01%. 1 The 0.05% concentration shows a small, not clinically meaningful rebound effect after discontinuation. 5

Age-Specific Considerations

Younger children require higher concentrations to achieve similar myopia control as older children receiving lower concentrations. 6

Age-dependent treatment response: 6

• 6-year-old children receiving 0.05% atropine achieved similar SE progression (-0.90 D) as:
  • 8-year-old children receiving 0.025% atropine (-0.89 D)
  • 10-year-old children receiving 0.01% atropine (-0.92 D)

Younger age is the only consistent factor associated with poorer treatment response across all concentrations studied. 6

Alternative Concentrations for Specific Scenarios

For Rapid Progressors (>0.75 D/year)

0.05% atropine demonstrates 62% reduction in progression rate in children with documented rapid myopia progression, reducing progression from -1.05±0.21 D/year to -0.4±0.14 D/year with no significant adverse effects. 7

For Older Children/Adolescents (8-15 years)

0.04% atropine may be considered as recent data shows superior efficacy compared to 0.01% atropine or orthokeratology in this age group (AL increase difference of 0.18 mm vs 0.01% over 2 years), though photophobia rates are higher (22.9% vs 2.1%). 8

For Minimal Side Effect Profile

0.01% atropine remains an option for children or families prioritizing minimal side effects over maximal efficacy, though efficacy is approximately half that of 0.05%. 1, 2 This concentration showed effectiveness over 5 years with fewer visual side effects compared to 0.1% or 0.5%. 1

Practical Implementation

Treatment should be administered once daily at bedtime in both eyes. 2, 5 All studied concentrations maintained stable efficacy in the second year of treatment, supporting sustained benefit with continued use. 2

Common pitfall to avoid: Underdosing with 0.01% in younger children (ages 6-8) who require higher concentrations for adequate myopia control. 6

Safety monitoring: Accommodation amplitude, pupil diameter, and visual acuity remain largely unaffected at 0.05% concentration, with no significant effect on retinal function demonstrated by multifocal electroretinograms after 2 years of daily use. 1